337 related articles for article (PubMed ID: 30430205)
1. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
4. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.
Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD
Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
6. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
7. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
9. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
10. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.
Iwami K; Shimato S; Ohno M; Okada H; Nakahara N; Sato Y; Yoshida J; Suzuki S; Nishikawa H; Shiku H; Natsume A; Wakabayashi T
Cytotherapy; 2012 Jul; 14(6):733-42. PubMed ID: 22424217
[TBL] [Abstract][Full Text] [Related]
11. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
[TBL] [Abstract][Full Text] [Related]
12. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
[TBL] [Abstract][Full Text] [Related]
13. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
[TBL] [Abstract][Full Text] [Related]
15. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
Obara W; Hara I; Kato Y; Kato R; Inoue K; Sato F; Mimata H; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2018 Sep; 67(9):1371-1380. PubMed ID: 29971464
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
19. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
[TBL] [Abstract][Full Text] [Related]
20. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP
BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]